(Reuters) - German healthcare group Fresenius reported fourth-quarter adjusted operating profit above market estimates on Wednesday, citing strong performance at its Kabi and Helios divisions.

The company's earnings before interest and taxes (EBIT) excluding special items rose to 646 million euros ($678 million) in the quarter ended December 31, compared to analysts' average estimate of 634 million euros in a poll compiled by Vara Research.

The results echo those of its former dialysis unit, Fresenius Medical Care, which topped market expectation on Tuesday helped by positive development across its businesses.

For 2025, Fresenius sees organic revenue growth before special items of between 4% and 6%, and constant currency EBIT growth in a range of 3% to 7%.

The company also said it would propose a dividend of 1 euro per share for the 2024 financial year.

($1 = 0.9527 euros)